Current Fungal Infection Reports

, Volume 6, Issue 1, pp 81–94 | Cite as

Is There Still a Place for Conventional Amphotericin B in the Treatment of Neonatal Fungal Infections?

  • Zoe-Dorothea Pana
  • Maria Ioannidou
  • Emmanuel RoilidesEmail author
Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)


Neonatal invasive fungal infections (IFIs) remain an increasing problem associated with high rates of morbidity and mortality, as well as late-onset neurodevelopmental implications. Invasive candidiasis remains the leading neonatal IFI. Candida albicans is the fungal species most often affecting this population, although a changing epidemiologic incidence to non-albicans Candida species is reported in some neonatal intensive care units. Many treatment recommendations are extrapolated from adult populations, emphasizing the need to establish the optimal antifungal agent, dosage, and duration of therapy in neonates. Historically, conventional amphotericin B has been considered an efficient and safe treatment approach for most neonatal IFIs. More recently, lipid formulations of amphotericin B have been studied, used alone or in combination with other antifungal agents such as azoles or echinocandins. The aim of this article is to review the published experience in the use of amphotericin B formulations to treat neonatal IFIs.


Neonates Infants Fungal infections Amphotericin B Treatment Antifungal agents Candida infection Candidiasis Drug combinations 



Conflicts of Interest: Z-D. Pana: none; M. Ioannidou: none; E. Roilides: Payment for speaking and development of educational presentations from Gilead, Cephalon, Pfizer, Schering, Merck, and Astellas.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Richardson DK, Gray JE, Gortmaker SL, et al. Declining severity adjusted mortality: evidence of improving neonatal intensive care. Pediatrics. 1998;102:893–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110:285–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Moran C, Benjamin D. Treatment of neonatal fungal infections. Adv Exp Med Biol. 2010;659:129–38.PubMedCrossRefGoogle Scholar
  4. 4.
    • Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect. 2010;16(9):1321–1327. This article is one of the most up-to-date expert reviews focusing on the problem of the increasing incidence of invasive fungal infections in children and neonates, their epidemiologic factors and outcome, outlining the differences in diagnosis and therapy between adult and pediatric populations. Further information about the scope and mission of the Multicentre International Pediatric Fungal Network (PFN) is provided. PubMedCrossRefGoogle Scholar
  5. 5.
    •• Blyth CC, Chen SC, Slavin MA, et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients; Australian Candidemia Study. Pediatrics. 2009;123(5):1360–1368. This prospective study by the Australian Candidemia Study Group analyzed and identified significant differences in the incidence of Candida infections, risk factors, treatment, and clinical outcome of candidemia in three subgroups (neonates, children and adults), emphasizing the need to develop different age-specific preventive and management guidelines. PubMedCrossRefGoogle Scholar
  6. 6.
    Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37(5):634–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48(12):1695–703.PubMedCrossRefGoogle Scholar
  8. 8.
    Kaufman D. Fungal infections in the very low birthweight infant. Curr Opin Infect Dis. 2004;17:253–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Almirante B, Rodríguez D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs. 2007;9(5):311–21.PubMedCrossRefGoogle Scholar
  10. 10.
    •• Roilides E. Invasive candidiasis in neonates and children. Early Hum Dev. 2011;87:75–76. This up-to-date review includes epidemiologic data, risk factors, clinical spectrum, and diagnostic procedures for invasive candidiasis in children and neonates. CrossRefGoogle Scholar
  11. 11.
    Makhoul IR, Sujov P, Smolkin T, et al. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics. 2002;109(1):34–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Long SS, Stevenson DK. Reducing Candida infections during neonatal intensive care: management choices, infection control, and fluconazole prophylaxis. J Pediatr. 2005;147(2):135–41.PubMedCrossRefGoogle Scholar
  13. 13.
    •• Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy—Is there a ‘right’ choice? Curr Opin Infect Dis. 2011;24(2):163–171. This up-to-date review summarizes the data about the differences in efficacy and safety of the amphotericin B formulations, deoxycholate and lipid amphotericin B, in the management of neonatal invasive fungal disease. The authors conclude that deoxycholate amphotericin B remains a safe and effective choice of therapy provided that potassium levels are monitored and renal function is not impaired. PubMedCrossRefGoogle Scholar
  14. 14.
    Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995–2004. Pediatrics. 2006;117(5):1680–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Benjamin Jr DK, Stoll BJ, Fanaroff AA, et al. National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117(1):84–92.PubMedCrossRefGoogle Scholar
  16. 16.
    Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients: the National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J. 2000;19(4):319–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Bayley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low birth weight infants: clinical manifestations and epidemiology. Pediatrics. 1984;73:144–52.Google Scholar
  18. 18.
    Faix RG, Kovarik SM, Shaw TR, et al. Mucocutaneous and invasive candidiasis among very low birth weight infants in intensive care nurseries: a prospective study. Pediatrics. 1989;83:101–7.PubMedGoogle Scholar
  19. 19.
    • Kaufman DA. Challenging issues in neonatal candidiasis. Current Med Res Opin. 2010;26(7):1769–1778. This review begins with the presentation of two cases involving neonates, providing the impetus for a discussion of issues concerning management (combination treatment, screening) and prevention guidelines (antifungal prophylaxis) in neonatal candidiasis. Five well-designed tables provide a summary and overview. CrossRefGoogle Scholar
  20. 20.
    Zaoutis TE, Heydon K, Localio R, et al. Outcomes attributable to neonatal candidiasis. Clin Infect Dis. 2007;44(9):1187–93.PubMedCrossRefGoogle Scholar
  21. 21.
    Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA. 2004;292(19):2357–65.PubMedCrossRefGoogle Scholar
  22. 22.
    Kaufman DA, Gurka MJ, Hazen KC, et al. Patterns of fungal colonization in preterm infants weighing less than 1000 grams at birth. Pediatr Infect Dis J. 2006;25:733–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J. 2001;20:1119–24.PubMedCrossRefGoogle Scholar
  24. 24.
    Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis. 2001;32:1018–23.PubMedCrossRefGoogle Scholar
  25. 25.
    Benjamin Jr DK, Poole C, Steinbach WJ, et al. Neonatal candidemia and end organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics. 2003;112:634–40.PubMedCrossRefGoogle Scholar
  26. 26.
    Smith PB, Steinbach WJ, Benjamin Jr DK. Neonatal candidiasis. Infect Dis Clin North Am. 2005;19:603–15.PubMedCrossRefGoogle Scholar
  27. 27.
    Faix RG, Chapman RL. Central nervous system candidiasis in the high-risk neonate. Semin Perinatol. 2003;27(5):384–92.PubMedCrossRefGoogle Scholar
  28. 28.
    Friedman S, Richardson SE, et al. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J. 2000;19(6):499–504.PubMedCrossRefGoogle Scholar
  29. 29.
    Fernandez M, Moylett EH, Noyola DE, Baker CJ. Candida meningitis in neonates: a 10-year review. Clin Infect Dis. 2000;31:458–63.PubMedCrossRefGoogle Scholar
  30. 30.
    Benjamin Jr DK, Stoll BJ, Gantz MG, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010;126:865–73.CrossRefGoogle Scholar
  31. 31.
    • Zaoutis T. Candidemia in children. Curr Med Res Opin. 2010 26(7):1761–1768. This review weighs risk factors, epidemiologic features, and management of pediatric candidemia. Treatment guidelines are subcategorized according to the child’s immunosuppression status (neutropenic vs non-neutropenic). It also provides the updated IDSA guidelines for the removal of intravenous catheters. PubMedCrossRefGoogle Scholar
  32. 32.
    Baradkar VP, Mathur M, Kumar S. Neonatal septicaemia in a premature infant due to Candida dubliniensis. Indian J Med Microbiol. 2008;26(4):382–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Benjamin Jr DK, Garges H, Steinbach WJ. Candida bloodstream infection in neonates. Semin Perinatol. 2003;27(5):375–83.PubMedCrossRefGoogle Scholar
  34. 34.
    Huang Y-C, Lin T-Y, Leu H-S, et al. Outbreak of Candida parapsilosis fungemia in neonatal intensive care units: clinical implications and genotyping analysis. Infection. 1999;27:97–102.PubMedCrossRefGoogle Scholar
  35. 35.
    Hernández-Castro R, Arroyo-Escalante S, Carrillo-Casas EM, et al. Outbreak of Candida parapsilosis in a neonatal intensive care unit: a health care workers source. Eur J Pediatr. 2010;169:783–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Lupetti A, Tavanti A, Davini P, et al. Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol. 2002;40:2363–9.PubMedCrossRefGoogle Scholar
  37. 37.
    van Asbeck EC, Huang YC, Markham AN, et al. Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies. Mycopathologia. 2007;164:287–93.PubMedCrossRefGoogle Scholar
  38. 38.
    Dizbay M, Kalkanci A, Sezer BE, et al. Molecular investigation of a fungemia outbreak due to Candida parapsilosis in an intensive care unit. Braz J Infect Dis. 2008;12:395–9.PubMedCrossRefGoogle Scholar
  39. 39.
    •• Montagna MT, Lovero G, De Giglio O, et al. Invasive fungal infections in neonatal intensive care units of Southern Italy: a multicentre regional active surveillance (AURORA project). J Prev Med Hyg. 2010;51(3):125–130. This prospective multicenter surveillance study evaluated the epidemiology of invasive fungal infections among infants admitted to NICUs, revealing the predominance of non-Candida spp. as well as the usefulness of (1,3)-beta-D glucan as a supplemental diagnostic test. PubMedGoogle Scholar
  40. 40.
    Faix RG. Invasive neonatal candidiasis: comparison of albicans and parapsilosis infection. Pediatr Infect Dis J. 1992;11(2):88–93.PubMedCrossRefGoogle Scholar
  41. 41.
    Levy I, Rubin LG, Vasishtha S, et al. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis. 1998;26(5):1086–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Benjamin Jr DK, Ross K, McKinney Jr RE, et al. When to suspect fungal infection in neonates: a clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics. 2000;106(4):712–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Roilides E, Farmaki E, Evdoridou J, et al. Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis. 2004;23(10):745–50.PubMedCrossRefGoogle Scholar
  44. 44.
    Fairchild KD, Tomkoria S. Neonatal Candida glabrata sepsis: clinical and laboratory features compared with other Candida species. Pediatr Infect Dis J. 2002;21(1):39–43.PubMedCrossRefGoogle Scholar
  45. 45.
    Marodi L, Johnston Jr RB. Invasive Candida species disease in infants and children: occurrence, risk factors, management, and innate host defense mechanisms. Curr Opin Pediatr. 2007;19:693–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Farmaki E, Evdoridou J, Pouliou T, et al. Fungal colonization in the neonatal intensive care unit: risk factors, drug susceptibility, and association with invasive fungal infections. Am J Perinatol. 2007;24:127–35.PubMedCrossRefGoogle Scholar
  48. 48.
    Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch Dis Child Fetal Neonatal Ed. 2006;91(3):188–92.CrossRefGoogle Scholar
  49. 49.
    Waggoner-Fountain LA, Whit Walker M, Hollis RJ, et al. Vertical and horizontal transmission of unique Candida species to premature newborns. Clin Infect Dis. 1996;22:803–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Reef SE, Lasker BA, Butcher DA, et al. Non perinatal nosocomial transmission of Candida albicans in a neonatal intensive care unit: prospective study. J Clin Microbiol. 1998;36:1255–9.PubMedGoogle Scholar
  51. 51.
    Benjamin DKJ, DeLong ER, Steinbach WJ, et al. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics. 2003;112:543–7.PubMedCrossRefGoogle Scholar
  52. 52.
    • Robinson JL, Davies HD, Barton M, et al. Characteristics and outcome of infants with candiduria in neonatal intensive care—A Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. BMC Infect Dis. 2009;23:183–193. This is a prospective, multicenter Canadian study evaluating the characteristics, treatment, and outcome of candidal urinary tract infection in infants in the NICU. CrossRefGoogle Scholar
  53. 53.
    Zaoutis TE, Coffin SE, Chu JH, et al. Risk factors for mortality in children with candidemia. Pediatr Infect Dis J. 2005;24:736–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Pasqualotto AC, de Moraes AB, Zanini RR, et al. Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect Control Hosp Epidemiol. 2007;28:799–804.PubMedCrossRefGoogle Scholar
  55. 55.
    Weese-Mayer DE, Fondriest DW, Brouillette RT, et al. Risk factors associated with candidemia in the neonatal intensive care unit: a case control study. Pediatr Infect Dis J. 1987;6:190–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Cotton CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118:717–22.CrossRefGoogle Scholar
  57. 57.
    Benjamin Jr DK, Ross K, McKinney Jr RE. When to suspect fungal infection in neonates: a clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics. 2000;106:712–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Guillet R, Stoll BJ, Cotten CM, Gantz M, McDonald S, Poole WK, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2006;117:137–42.CrossRefGoogle Scholar
  59. 59.
    Botas CM, Kurlat I, Young SM, et al. Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics. 1995;95:883–7.PubMedGoogle Scholar
  60. 60.
    Pera A, Byun A, Gribar S, et al. Dexamethasone therapy and Candida sepsis in neonates less than 1250 grams. J Perinatol. 2002;22:204–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Campbell JR, Zaccaria E, Baker CJ. Systemic candidiasis in extremely low birth weight infants receiving topical petrolatum ointment for skin care: a case–control study. Pediatrics. 2000;105:1041–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Shetty SS, Harrison LH, Hajjeh RA, et al. Determining risk factors for candidemia among newborn infants from population-based surveillance: Baltimore, Maryland, 1998–2000. Pediatr Infect Dis J. 2005;24:601–4.PubMedCrossRefGoogle Scholar
  63. 63.
    Zaoutis TE, Roilides E, Chiou CC, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J. 2007;26:723–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Roilides E, Zaoutis TE, Katragkou A, Benjamin Jr DK, Walsh TJ. Zygomycosis in neonates: an uncommon but life-threatening infection. Am J Perinatol. 2009;26(8):565–73.PubMedCrossRefGoogle Scholar
  65. 65.
    Stock C, Veyrier M, Magnin-Verschelde S, et al. Primary cutaneous aspergillosis complicated with invasive aspergillosis in an extremely preterm infant: case report and literature review. Arch Pediatr. 2010;17(10):1455–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Erişir-Oygucu S, Akcan AB, Oygür N. Primary cutaneous aspergillosis in an extremely low birth weight preterm. Turk J Pediatr. 2009;51(6):621–3.PubMedGoogle Scholar
  67. 67.
    Galimberti R, Kowalczuk A, Hidalgo Parra I, Gonzalez Ramos M, Flores V. Cutaneous aspergillosis: a report of six cases. Br J Dermatol. 1998;139:522–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Woodruff CA, Hebert AA. Neonatal primary cutaneous aspergillosis: case report and review of the literature. Pediatr Dermatol. 2002;19:439–44.PubMedCrossRefGoogle Scholar
  69. 69.
    Groll AH, Jaeger G, Allendorf A, Herrmann G, Schloesser R, von Loewenich V. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis. 1998;27:437–52.PubMedCrossRefGoogle Scholar
  70. 70.
    Singer S, Singer D, Ruchel R, Mergeryan H, Schmidt U, Harms K. Outbreak of systemic aspergillosis in a neonatal intensive care unit. Mycoses. 1998;41:223–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Schwartz DA, Jacquette M, Chawla HS. Disseminated neonatal aspergillosis: report of a fatal case and analysis of risk factors. Pediatr Infect Dis J. 1998;7:349–53.Google Scholar
  72. 72.
    Fuchs H, von Baum H, Meth M, et al. CNS-manifestation of aspergillosis in an extremely low-birth-weight infant. Eur J Pediatr. 2006;165(7):476–80.PubMedCrossRefGoogle Scholar
  73. 73.
    Herron MD, Vanderhooft SL, Byington C, King JD. Aspergillosis in a 24-week newborn: a case report. J Perinatol. 2003;23(3):256–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Powell DA, Hayes J, Durell DE, Miller M, Marcon MJ. Malassezia furfur skin colonization of infants hospitalized in intensive care units. J Pediatr. 1987;111:217–20.PubMedCrossRefGoogle Scholar
  75. 75.
    Long JG, Keyserling HL. Catheter-related infection in infants due to an unusual lipophilic yeast Malassezia furfur. Pediatrics. 1985;76:896–900.PubMedGoogle Scholar
  76. 76.
    Koseki S, Takahashi S. Serial observation on the colonization of Pityrosporum orbiculare (ovale) on the facial skin surface of newborn infants. Jpn J Med Mycol. 1988;29:209–15.CrossRefGoogle Scholar
  77. 77.
    Rapelanoro R, Mortureux P, Couprie B, Maleville J, Taıeb A. Neonatal Malassezia furfur pustulosis. Arch Dermatol. 1996;132:190–3.PubMedCrossRefGoogle Scholar
  78. 78.
    Patrizi A, Bardazzi F, Neri I, Varotti E. La pustolosi neonatale da Malassezia furfur. Giorn Int Derm Ped. 1996;8:3.Google Scholar
  79. 79.
    Rowen JL, Tate JM. Management of neonatal candidiasis. Neonatal Candidiasis Study Group. Pediatr Infect Dis J. 1998;17:1007–11.PubMedCrossRefGoogle Scholar
  80. 80.
    Baley JE, Meyers C, Kliegman RM, Jacobs MR, Blumer JL. Pharmacokinetics, outcome of treatment, and toxic effects of Amphotericin B and 5-fluorocytosine in neonates. J Pediatr. 1990;116:791–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother. 2000;12:463–70.PubMedGoogle Scholar
  82. 82.
    Zaoutis TH, Walsh T. Antifungal therapy for neonatal candidiasis. Curr Opin Infect Dis. 2007;20:592–7.PubMedCrossRefGoogle Scholar
  83. 83.
    Carter JE, Laurini JA, Evans TN, Estrada B. Neonatal Candida parapsilosis meningitis and empyema related to epidural migration of a central venous catheter. Clin Neurol Neurosurg. 2008;110(6):614–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Kingo AR, Smyth JA, Waisman D. Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr Inf Dis J. 1997;16:1002–3.CrossRefGoogle Scholar
  85. 85.
    Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy. 2001;21:133–48.CrossRefGoogle Scholar
  86. 86.
    Ellis M, Amphotericin B. preparations: a maximum tolerated dose in severe invasive fungal infections? Transpl Infect Dis. 2000;2:51–61.PubMedCrossRefGoogle Scholar
  87. 87.
    Jeon GW, Koo SH, Lee JH, et al. A comparison of Am Bisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants. Yonsei Med J. 2007;48(4):619–26.PubMedCrossRefGoogle Scholar
  88. 88.
    Holler B, Omar SA, Maged DF, Patterson JM. Effects of fluid and electrolyte management on Amphotericin B-induced nephrotoxicity among extremely low birth weight infants. Pediatrics. 2004;113:608–16.CrossRefGoogle Scholar
  89. 89.
    •• Turcu R, Patterson MJ, Omar S. Influence of sodium intake on Amphotericin B-induced nephrotoxicity among extremely premature infants. Pediatr Nephrol. 2009;24:497–505. The aim of this study was to evaluate the effect of high sodium intake (> 4 mEq/kg per day) on the incidence of AMB-induced nephrotoxicity among extremely premature infants with birth weight <1250 g. According to the authors’ observations, high sodium intake was associated with a reduced incidence of AMB-induced nephrotoxicity. PubMedCrossRefGoogle Scholar
  90. 90.
    Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother. 2002;49(1):37–41.PubMedCrossRefGoogle Scholar
  91. 91.
    Bayley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr. 1990;116:791–7.CrossRefGoogle Scholar
  92. 92.
    Starke JR, Mason Jr EO, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis. 1995;155:766–74.CrossRefGoogle Scholar
  93. 93.
    Kingo AR, Smyth JA, Waisman D. Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr Infect Dis J. 1997;16:1002–3.PubMedCrossRefGoogle Scholar
  94. 94.
    Butler KM, Rench MA, Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J. 1990;9:51–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother. 2003;52:663–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Rowen JL, Tate JM. For the neonatal candidasis study group. Management of neonatal candidiasis. Pediatr Infect Dis J. 1998;17:1007–11.PubMedCrossRefGoogle Scholar
  97. 97.
    Benjamin Jr DK, Fisher RG, McKinney Jr RE, Benjamin DK. Candidal mycetoma in the neonatal kidney. Pediatrics. 1999;104:1126–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Berman LH, Stringer DA, St. Onge AD, et al. An assessment of sonography in the diagnosis and management of neonatal renal candidiasis. Clin Radiol. 1989;40:577–81.PubMedCrossRefGoogle Scholar
  99. 99.
    Stein RS, Alexander JA. Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am J Med Sci. 1989;298:299–304.PubMedCrossRefGoogle Scholar
  100. 100.
    Heideman H. Prevention of amphotericin B nephrotoxicity: the effect of salt loading and flucytosine. Mycoses. 1988;31 Suppl 2:39–44.Google Scholar
  101. 101.
    Gardner ML, Godley PJ, Wasan SM. Sodium loading treatment for amphotericin B-induced nephrotoxicity. DICP Ann Pharmacother. 1990;24:940–46.Google Scholar
  102. 102.
    Sabra R, Branch RA. Mechanisms of amphotericin B induced decrease in glomerular filtration rate in rats. Antimicrob Agents Chemother. 1991;35:2509–14.PubMedGoogle Scholar
  103. 103.
    Llanos A, Cieza J, Bernado J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int. 1991;40:302–8.PubMedCrossRefGoogle Scholar
  104. 104.
    Adler-Moore J, Proffitt RT. Am Bisome: liposomal formulation, structure, mechanism of action and preclinical experience. J Antimicrob Chemother. 2002;49:21–30.PubMedCrossRefGoogle Scholar
  105. 105.
    Würthwein G, Groll AH, Hempel G, et al. Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates. Antimicrob Agents Chemother. 2005;49:5092–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet. 1992;23:279–91.PubMedCrossRefGoogle Scholar
  107. 107.
    Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383–96.PubMedCrossRefGoogle Scholar
  108. 108.
    Walsh TJ, Seibel NL, Arndt C, Harris RE, Dinubile MJ, Reboli A, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J. 1999;18:702–8.PubMedCrossRefGoogle Scholar
  109. 109.
    Lackner H, Schwinger W, Urban C, et al. Liposomal amphotericin-B (AmBisome) for treatment of disseminated fungal infections in two infants of very low birth weight. Pediatrics. 1992;89:1259–61.PubMedGoogle Scholar
  110. 110.
    Scarcella A, Pasquariello M, Giuliano B, Vendemmia M, De Lucia A. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J. 1998;17:146–8.PubMedCrossRefGoogle Scholar
  111. 111.
    Bekersky I, Fielding RM, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002;46(3):828–33.PubMedCrossRefGoogle Scholar
  112. 112.
    Juster-Reicher A, Flidel-Rimon O, Amitay M, et al. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis. 2003;22:603–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Weitkamp JH, Poets CF, Sievers R, Musswessels E, Groneck P, Thomas P, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome®). Infection. 1998;26:11–5.PubMedCrossRefGoogle Scholar
  114. 114.
    Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection. 2000;28:223–6.PubMedCrossRefGoogle Scholar
  115. 115.
    Cetin H, Yalaz M, Akisu M, et al. The efficacy of two different lipid-based amphotericin B in neonatal Candida septicemia. Pediatr Int. 2005;47(6):676–80.PubMedCrossRefGoogle Scholar
  116. 116.
    • Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J. 2009;28:1061–1063. This retrospective study analyzed the prevalence of nephrotoxicity in neonates receiving DAMB. Demographic, therapeutic, microbiologic, and laboratory data revealed that DAMB administration in this study population caused a transient impairment of renal function that should be closely monitored. PubMedCrossRefGoogle Scholar
  117. 117.
    Carrasco Sánchez P, Castillo Montero ML, Bejarano Palma A, et al. Neonatal candidiasis and liposomal amphotericin B treatment: our experience. An Esp Pediatr. 1999;51(3):273–80.PubMedGoogle Scholar
  118. 118.
    •• Auron A, Auron-Gomez M, Raina R, Viswanathan S, Mhanna MJ. Effect of amphotericin B lipid complex (ABLC) in very low birth weight infants. Pediatr Nephrol. 2009;24:295–299. This retrospective case control study evaluated the possible nephrotoxic effect of amphotericin B lipid complex in VLBW infants by measuring serum creatinine, blood urea nitrogen, and sodium and potassium levels during treatment lasting at least 2 weeks. No substantial changes in these laboratory data were observed. PubMedCrossRefGoogle Scholar
  119. 119.
    Adler-Shohet F, Waskin H, Lieberman JM. Amphotericin B lipid complex for neonatal invasive candidiasis. Arch Dis Child Fetal Neonatal Ed. 2001;84:131–3.CrossRefGoogle Scholar
  120. 120.
    Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin invasive candidiasis study group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27(9):820–6.PubMedCrossRefGoogle Scholar
  121. 121.
    López Sastre JB, Coto Cotallo GD, Fernández Colomer B. Grupo de Hospitales Castrillo. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol. 2003;20:153–63.PubMedCrossRefGoogle Scholar
  122. 122.
    Hope WW, Warn PA, Sharp A, et al. Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. Antimicrob Agents Chemother. 2007;51:3760–2.PubMedCrossRefGoogle Scholar
  123. 123.
    Karatza AA, Dimitriou G, Marangos M, et al. Successful resolution of cardiac mycetomas by combined liposomal amphotericin B with fluconazole treatment in premature neonates. Eur J Pediatr. 2008;167:1021–3.PubMedCrossRefGoogle Scholar
  124. 124.
    Levy I, Shalit I, Birk E, et al. Candida endocarditis in neonates: report of five cases and review of the literature. Mycoses. 2006;49:43–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Stocker M, Caduff JH, Spalinger J, Berger TM. Successful treatment of bilateral renal fungal balls with liposomal amphotericin B and fluconazole in an extremely low birth weight infant. Eur J Pediatr. 2000;159(9):676–8.PubMedCrossRefGoogle Scholar
  126. 126.
    Wald M, Lawrenz K, Kretzer V, et al. A very low birth weight infant with Candida nephritis with fungus balls. Full recovery after pyelotomy and antifungal combination therapy. Eur J Pediatr. 2003;162(9):642–3.PubMedCrossRefGoogle Scholar
  127. 127.
    Turan O, Ergenekon E, Hirfanoğlu IM, et al. Combination antifungal therapy with voriconazole for persistent candidemia in very low birth weight neonates. Turk J Pediatr. 2011;53:19–26.PubMedGoogle Scholar
  128. 128.
    Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J. 2004;23:1093–7.PubMedGoogle Scholar
  129. 129.
    Natarajan G, Lulic-Botica M, Rongkavilit C, et al. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol. 2005;25:770–7.PubMedCrossRefGoogle Scholar
  130. 130.
    Haase R, Kreft B, Foell J, et al. Successful treatment of Candida albicans septicemia in a preterm infant with severe congenital ichthyosis (Harlequin baby). Pediatr Dermatol. 2009;26:575–8.PubMedCrossRefGoogle Scholar
  131. 131.
    Belet N, Ciftçi E, Ince E, et al. Caspofungin treatment in two infants with persistent fungaemia due to Candida lipolytica. Scand J Infect Dis. 2006;38:559–62.PubMedCrossRefGoogle Scholar
  132. 132.
    • Natarajan G, Lulic-Botica M, Aranda JV. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J Perinatol. 2009;29:738–743. This study compared the clinical features and prognosis of two subgroups of preterm neonates with candidemia: good responders to conventional antifungals versus those with refractory candidemia. It also evaluated the clinical efficacy of high-dose micafungin pharmacotherapy in refractory neonatal candidemia. Refractory candidemia has been associated with poor outcome despite high-dose micafungin pharmacotherapy in combination with conventional antifungals. PubMedCrossRefGoogle Scholar
  133. 133.
    Varisco BM, Benner KW, Prabhakaran P. Neonatal peritoneal candidiasis successfully treated with anidulafungin add-on therapy. Ann Pharmacother. 2009;43:1907–10.PubMedCrossRefGoogle Scholar
  134. 134.
    Groll AH, Jaeger G, Allendorf A, et al. Invasive pulmonary aspergillosis in a critically ill neonate: Case report and review of invasive aspergillosis during the first three months of life. Clin Infect Dis. 1998;27:437–52.PubMedCrossRefGoogle Scholar
  135. 135.
    Herron MD, Vanderhooft SL, Byington C, et al. Aspergillosis in a 24-week newborn: a case report. J Perinatol. 2003;23(3):256–9.PubMedCrossRefGoogle Scholar
  136. 136.
    Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121(5):1286–94.CrossRefGoogle Scholar
  137. 137.
    Fuchs H, von Baum H, Meth M, et al. CNS-manifestation of aspergillosis in an extremely low-birth-weight infant. Eur J Pediatr. 2006;165(7):476–80.PubMedCrossRefGoogle Scholar
  138. 138.
    •• Pappas PG, Kaufmann CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–535. These updated guidelines have replaced the previous guidelines of 2004 concerning the therapeutic management of candidiasis. These guidelines include therapeutic recommendations as well as prospective data on the prevention of neonatal candidiasis. PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Zoe-Dorothea Pana
    • 1
  • Maria Ioannidou
    • 1
  • Emmanuel Roilides
    • 1
    Email author
  1. 1.3rd Department of PediatricsHippokration HospitalThessalonikiGreece

Personalised recommendations